Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, IDEAYA Biosciences, Inc. reported revenue of $219M, up 3024.4% year over year. Operating margin was -72.8% and net margin -52.0%, on a free-cash-flow margin of -33.6% with capital expenditure at 1.1% of revenue. Every figure is computed directly from IDYA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $219M | -72.8% | -52.0% |
| FY2024 | $7M | -4671.1% | -3921.1% |
| FY2023 | $23M | -574.9% | -483.0% |
| FY2022 | $51M | -122.7% | -115.2% |
| FY2021 | $28M | -179.9% | -178.1% |
How does IDYA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.